5Pong A, Thomson KS, Moland ES, et al. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin[J]. J Antimicrob Chemother, 1999,44(5):621-627
6Culley CM, Lacy MK, Klutman N, et al. Moxifloxacin: Clinical efficacy and safety[J]. Am J Health Syst Pharm, 2001,58(5):379-388
7Wise R, Andrews JM, Marshall G, et al. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration[J]. Antimicrob Agents Chemother, 1999,43(6):1508-1510
8Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man[J]. J Antimicrob Chemother, 1999,443(Suppl B):83-90
9Baz MN, Jannetti W, Villanueva C, et al. The efficacy and tolerability of moxifloxacin compared to trovafloxacin in the treatment of acute sinusitis[J]. Todays Ther Trends, 1999,17(2):303-319
10Burke T, Villanueva C, Mariano H, et al. Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis[J]. Clin Ther , 1999, 21(10):1664-1677
7World Health Organization. Global Tuberculosis Control 2011[M].Geneva:World Health Organization,2011.
8Villemagne B,Crauste C,Flipo M. Tuberculosis:The drug development pipeline at a glance European[J].Journal of Medicinal Chemistry,2012,(01):1-16.
9The Union Tuberculosis. The International Union Against Tuberculosis and Lung Disease[EB/OL].http://www.theunion.org/tuberculosis/tuberc ulosis.html,2012.
10Frieden T R,Sterling T R,Munsiff S S. Tuberculosis (Seminar)[J].The Lancet,2003.887-899.
